KR20160128428A - 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물 - Google Patents
오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물 Download PDFInfo
- Publication number
- KR20160128428A KR20160128428A KR1020167029704A KR20167029704A KR20160128428A KR 20160128428 A KR20160128428 A KR 20160128428A KR 1020167029704 A KR1020167029704 A KR 1020167029704A KR 20167029704 A KR20167029704 A KR 20167029704A KR 20160128428 A KR20160128428 A KR 20160128428A
- Authority
- KR
- South Korea
- Prior art keywords
- substituted
- pyridine
- carboxylate
- diazepine
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *C(C(*)=O)=*N(CCNCC1)C1=* Chemical compound *C(C(*)=O)=*N(CCNCC1)C1=* 0.000 description 2
- GSZFNXHTROPCPL-VXGBXAGGSA-N CC(C)(C)OC(N1CC[n]2nc(C(N(CC[C@H]3N4)C[C@H]3OC4=O)=O)nc2CC1)=O Chemical compound CC(C)(C)OC(N1CC[n]2nc(C(N(CC[C@H]3N4)C[C@H]3OC4=O)=O)nc2CC1)=O GSZFNXHTROPCPL-VXGBXAGGSA-N 0.000 description 1
- CURXYDUUGXYNRH-UHFFFAOYSA-N CCc(cc(cc1)C#N)c1OCC(O)=O Chemical compound CCc(cc(cc1)C#N)c1OCC(O)=O CURXYDUUGXYNRH-UHFFFAOYSA-N 0.000 description 1
- OSDIQCRELWDETA-UHFFFAOYSA-N O=C(CCc(cc1F)ccc1OC(F)F)N(CCc1c2)CC[n]1nc2C(N(CC1)Cc2c1[nH]nn2)=O Chemical compound O=C(CCc(cc1F)ccc1OC(F)F)N(CCc1c2)CC[n]1nc2C(N(CC1)Cc2c1[nH]nn2)=O OSDIQCRELWDETA-UHFFFAOYSA-N 0.000 description 1
- VKVXAFZJLAELDA-UHFFFAOYSA-N O=C(c1n[n](CCN(CC2)C(OCc(cc3F)ccc3OC(F)(F)F)=O)c2c1)N(CC1)Cc2c1[nH]nn2 Chemical compound O=C(c1n[n](CCN(CC2)C(OCc(cc3F)ccc3OC(F)(F)F)=O)c2c1)N(CC1)Cc2c1[nH]nn2 VKVXAFZJLAELDA-UHFFFAOYSA-N 0.000 description 1
- JCJXPQUDQXMSLG-RFZPGFLSSA-N O=C1O[C@H](CNCC2)[C@@H]2N1 Chemical compound O=C1O[C@H](CNCC2)[C@@H]2N1 JCJXPQUDQXMSLG-RFZPGFLSSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14161756.3 | 2014-03-26 | ||
| EP14161756 | 2014-03-26 | ||
| PCT/EP2015/056041 WO2015144609A1 (en) | 2014-03-26 | 2015-03-23 | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160128428A true KR20160128428A (ko) | 2016-11-07 |
Family
ID=50389847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167029704A Ceased KR20160128428A (ko) | 2014-03-26 | 2015-03-23 | 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물 |
Country Status (19)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104364239B (zh) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
| ES2753163T3 (es) | 2012-09-25 | 2020-04-07 | Hoffmann La Roche | Derivados de hexahidropirrolo[3,4-c]pirrol y compuestos relacionados como inhibidores de la autotaxina (ATX) y como inhibidores de la producción de ácido lisofosfatídico (LPA) para tratar, por ejemplo, enfermedades renales |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| CA2923523A1 (en) | 2013-11-26 | 2015-06-04 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl |
| WO2015116904A1 (en) | 2014-02-03 | 2015-08-06 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
| JP6554481B2 (ja) | 2014-03-26 | 2019-07-31 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | オートタキシン（ａｔｘ）及びリゾホスファチジン酸（ｌｐａ）産生の阻害剤としての縮合［１，４］ジアゼピン化合物 |
| SG11201607839UA (en) | 2014-03-26 | 2016-10-28 | Hoffmann La Roche | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| WO2017024018A1 (en) | 2015-08-05 | 2017-02-09 | Vitae Pharmaceuticals, Inc. | Modulators of ror-gamma |
| CA2992889A1 (en) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| EP3353181B1 (en) | 2015-09-24 | 2021-08-11 | F. Hoffmann-La Roche AG | Bicyclic compounds as dual atx/ca inhibitors |
| JP6877413B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重ａｔｘ／ｃａ阻害剤としての新規な二環式化合物 |
| WO2017050792A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| CA2983782A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| TW201831478A (zh) * | 2016-12-02 | 2018-09-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環醯胺化合物及其使用方法 |
| KR20190129924A (ko) * | 2017-03-16 | 2019-11-20 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물 |
| WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
| EP4397309A3 (en) | 2017-07-14 | 2024-09-04 | F. Hoffmann-La Roche AG | Bicyclic ketone compounds and methods of use thereof |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| BR112020001246A2 (pt) | 2017-07-24 | 2020-07-21 | Vitae Pharmaceuticals, Llc | inibidores de rory |
| EP3704097B1 (en) | 2017-10-31 | 2023-10-25 | F. Hoffmann-La Roche AG | Bicyclic sulfones and sulfoxides and methods of use thereof |
| JP7585205B2 (ja) | 2019-01-11 | 2024-11-18 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二環式ピロロトリアゾールケトン化合物及びその使用方法 |
| AU2022356017B2 (en) * | 2021-10-01 | 2024-05-30 | Nextgen Bioscience Co., Ltd. | Novel piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same |
Family Cites Families (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1252898B (de) | 1965-06-12 | 1967-10-26 | Bayer Ag | Verfahren zur Herstellung von Copolymerisaten des Trioxans |
| US5240928A (en) | 1989-07-03 | 1993-08-31 | Merck & Co., Inc. | Substituted quinazolinones as angiotensin II antagonists |
| DE3930262A1 (de) | 1989-09-11 | 1991-03-21 | Thomae Gmbh Dr K | Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| CA2037630C (en) | 1990-03-07 | 2001-07-03 | Akira Morimoto | Nitrogen-containing heterocylic compounds, their production and use |
| US5470975A (en) | 1990-10-16 | 1995-11-28 | E.R. Squibb & Sons, Inc. | Dihydropyrimidine derivatives |
| US5290780A (en) | 1991-01-30 | 1994-03-01 | American Cyanamid Co. | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| US5238942A (en) | 1991-05-10 | 1993-08-24 | Merck & Co., Inc. | Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists |
| US5202322A (en) | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
| US5532243A (en) | 1992-02-14 | 1996-07-02 | The Dupont Merck Pharmaceutical Company | Antipsychotic nitrogen-containing bicyclic compounds |
| US5358951A (en) | 1993-04-23 | 1994-10-25 | American Cyanamid Company | Angiotensin II receptor blocking 2, 3, 6 substituted quinazolinones |
| DE4407047A1 (de) | 1994-03-03 | 1995-09-07 | Merck Patent Gmbh | Acetamide |
| US20010016657A1 (en) | 1997-03-18 | 2001-08-23 | Smithkline Beecham P.L.C. | Substituted isoquinoline derivatives and their use as anticonvulsants |
| WO1999040070A1 (en) | 1998-02-04 | 1999-08-12 | Banyu Pharmaceutical Co., Ltd. | N-acyl cyclic amine derivatives |
| JP2001039950A (ja) | 1999-07-30 | 2001-02-13 | Banyu Pharmaceut Co Ltd | Ｎ−アシル環状アミン誘導体 |
| WO2001030780A2 (en) | 1999-10-27 | 2001-05-03 | Cor Therapeutics, Inc. | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| EP1368354A1 (en) | 2001-03-07 | 2003-12-10 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
| CA2481313A1 (en) | 2002-04-12 | 2003-10-23 | Merck & Co., Inc. | Bicyclic amides |
| GB0303852D0 (en) | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| WO2005023762A1 (en) | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| SE0302811D0 (sv) | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| GB0324790D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
| US7226951B2 (en) | 2003-12-17 | 2007-06-05 | Allergan, Inc. | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same |
| JP4845873B2 (ja) | 2004-03-03 | 2011-12-28 | ケモセントリックス インコーポレーティッド | 二環式および架橋した窒素複素環 |
| WO2005121145A2 (en) | 2004-06-09 | 2005-12-22 | F. Hoffmann-La Roche Ag | Octahydro-pyrrolo[3,4-c] derivatives and their use as antiviral compounds |
| ES2442857T3 (es) | 2004-08-10 | 2014-02-13 | Janssen Pharmaceutica Nv | Derivados de 1,2,4-triazin-6-ona inhibidores de VIH |
| US7410949B2 (en) | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
| MX2007013469A (es) | 2005-04-28 | 2008-01-22 | Wyeth Corp | Forma ii polimorfa de tanaproget. |
| US7737279B2 (en) | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
| TW200800999A (en) | 2005-09-06 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| US8318931B2 (en) | 2005-10-28 | 2012-11-27 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonists and use thereof |
| EP1961744B1 (en) | 2005-11-18 | 2013-04-17 | Ono Pharmaceutical Co., Ltd. | Basic group-containing compound and use thereof |
| WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
| JP2008031064A (ja) | 2006-07-27 | 2008-02-14 | Astellas Pharma Inc | ジアシルピペラジン誘導体 |
| WO2008033764A2 (en) | 2006-09-11 | 2008-03-20 | N.V. Organon | Quinazolinone and isoquinolinone acetamide derivatives |
| CN101541795A (zh) | 2006-09-15 | 2009-09-23 | 先灵公司 | 用于治疗疼痛、糖尿病和脂类代谢紊乱的螺-稠合氮杂环丁烷衍生物 |
| US8735411B2 (en) | 2006-10-02 | 2014-05-27 | Abbvie Inc. | Macrocyclic benzofused pyrimidine derivatives |
| ATE523497T1 (de) | 2006-11-15 | 2011-09-15 | High Point Pharmaceuticals Llc | Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen |
| TW200831085A (en) | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
| EP1975165A1 (de) | 2007-03-27 | 2008-10-01 | Boehringer Ingelheim Pharma GmbH & Co. KG | Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel |
| EP2142520A1 (en) | 2007-03-29 | 2010-01-13 | F. Hoffmann-Roche AG | Non-nucleoside reverse transcriptase inhibitors |
| CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| JP2010524987A (ja) | 2007-04-27 | 2010-07-22 | サノフィ−アベンティス | ２−ヘテロアリール−ピロロ［３，４−ｃ］ピロール誘導体及びｓｃｄ阻害剤としてのそれらの使用 |
| DE102007047737A1 (de) | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| MX2010004281A (es) | 2007-10-19 | 2010-09-10 | Sarcode Corp | Composiciones y metodos para el tratamiento de la retinopatia diabetica. |
| TW200932236A (en) | 2007-10-31 | 2009-08-01 | Janssen Pharmaceutica Nv | Aryl-substituted bridged diamines as modulators of leukotriene A4 hydrolase |
| JP2009161449A (ja) | 2007-12-28 | 2009-07-23 | Lion Corp | Ｐｐａｒ活性促進剤並びに美容用飲食品、皮膚外用剤及び医薬 |
| EP2301936A1 (en) | 2008-06-19 | 2011-03-30 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
| WO2010028761A1 (de) | 2008-09-09 | 2010-03-18 | Sanofi-Aventis | 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren |
| TW201020247A (en) | 2008-11-06 | 2010-06-01 | Gruenenthal Gmbh | Substituierte disulfonamide |
| CA2739725A1 (en) | 2008-11-17 | 2010-05-20 | F. Hoffmann-La Roche Ag | Naphthylacetic acids used as crth2 antagonists or partial agonists |
| DE102008059578A1 (de) | 2008-11-28 | 2010-06-10 | Merck Patent Gmbh | Benzo-Naphtyridin Verbindungen |
| AU2009321867B2 (en) | 2008-12-01 | 2015-12-10 | Merck Patent Gmbh | 2,5-Diamino-substituted pyrido[4,3-d]pyrimidines as autotaxin inhibitors against cancer |
| TW201035102A (en) | 2009-03-04 | 2010-10-01 | Gruenethal Gmbh | Sulfonylated tetrahydroazolopyrazines and their use as medicinal products |
| TW201038572A (en) | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
| CN102369195B (zh) | 2009-04-02 | 2014-04-16 | 默克专利有限公司 | 自分泌运动因子抑制剂 |
| JP5591318B2 (ja) | 2009-04-02 | 2014-09-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | オートタキシン阻害剤としてのピペリジンおよびピペラジン誘導体 |
| BRPI1009800A2 (pt) | 2009-04-02 | 2016-03-15 | Merck Patent Gmbh | compostos heterocíclicos como inibidores de autotaxina |
| FR2945534B1 (fr) | 2009-05-12 | 2012-11-16 | Sanofi Aventis | DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
| KR20120034666A (ko) | 2009-05-22 | 2012-04-12 | 엑셀리시스, 인코포레이티드 | 증식성 질환에 대한 벤족사제핀 기반 ｐ１３ｋ／ｍｔ０ｒ의 억제제 |
| WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| DE102009033392A1 (de) | 2009-07-16 | 2011-01-20 | Merck Patent Gmbh | Heterocyclische Verbindungen als Autotaxin-Inhibitoren II |
| WO2011017350A2 (en) | 2009-08-04 | 2011-02-10 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
| UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
| AR079022A1 (es) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
| WO2011085170A1 (en) | 2010-01-07 | 2011-07-14 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
| WO2011115813A1 (en) | 2010-03-18 | 2011-09-22 | Abbott Laboratories | Lactam acetamides as calcium channel blockers |
| KR101455917B1 (ko) | 2010-03-19 | 2014-11-03 | 화이자 인코포레이티드 | 2,3-디히드로-1h-인덴-1-일-2,7-디아자스피로[3.5]노난 유도체 및 그렐린 수용체의 길항제 또는 역 작용제로서의 그 용도 |
| ES2562183T3 (es) | 2010-03-26 | 2016-03-02 | Merck Patent Gmbh | Benzonaftiridinaminas como inhibidores de la autotaxina |
| GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2011151461A2 (en) * | 2010-06-04 | 2011-12-08 | B.S.R.C. "Alexander Fleming" | Autotaxin pathway modulation and uses thereof |
| AR082590A1 (es) | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| ES2646834T3 (es) | 2010-08-20 | 2017-12-18 | Amira Pharmaceuticals, Inc. | Inhibidores de autotaxina y usos de los mismos |
| US8859775B2 (en) | 2010-09-02 | 2014-10-14 | Merck Patent Gmbh | Pyrazolopyridinone derivatives as LPA receptor antagonists |
| JP2014503528A (ja) | 2010-12-14 | 2014-02-13 | エレクトロプホレトイクス リミテッド | カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用 |
| US9260416B2 (en) | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
| ES2609579T3 (es) | 2011-08-29 | 2017-04-21 | VIIV Healthcare UK (No.5) Limited | Derivados espiro de diamina bicíclica como inhibidores de la unión del VIH |
| WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
| JPWO2013065712A1 (ja) | 2011-10-31 | 2015-04-02 | 東レ株式会社 | ジアザスピロウレア誘導体及びその医薬用途 |
| US8809552B2 (en) | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
| CA2856946C (en) | 2011-12-02 | 2016-08-02 | Phenex Pharmaceuticals Ag | Pyrrolo carboxamides as modulators of orphan nuclear receptor rar-related orphan receptor-gamma (rory, nr1f3) activity and for the treatment of chronic inflammatory and autoimmunediseases |
| TWI638802B (zh) | 2012-05-24 | 2018-10-21 | 芬蘭商奧利安公司 | 兒茶酚ｏ－甲基轉移酶活性抑制化合物 |
| EP3495367B1 (en) | 2012-06-13 | 2020-09-30 | Incyte Holdings Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| CN104364239B (zh) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
| MY171486A (en) | 2012-07-27 | 2019-10-15 | Biogen Ma Inc | Atx modulating agents |
| MX362346B (es) | 2012-07-27 | 2019-01-11 | Biogen Ma Inc | Compuestos que son agentes moduladores de s1p y/o agentes moduladores de autotaxina. |
| MY183969A (en) | 2012-09-25 | 2021-03-17 | Bayer Pharma AG | Combination of regorafenib and acetylsalicylic acid for treating cancer |
| ES2753163T3 (es) | 2012-09-25 | 2020-04-07 | Hoffmann La Roche | Derivados de hexahidropirrolo[3,4-c]pirrol y compuestos relacionados como inhibidores de la autotaxina (ATX) y como inhibidores de la producción de ácido lisofosfatídico (LPA) para tratar, por ejemplo, enfermedades renales |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| AU2013334236B2 (en) | 2012-10-25 | 2018-04-05 | Tetra Discovery Partners, Llc. | Heteroaryl inhibitors of PDE4 |
| JPWO2014133112A1 (ja) | 2013-03-01 | 2017-02-02 | 国立大学法人 東京大学 | オートタキシン阻害活性を有する８−置換イミダゾピリミジノン誘導体 |
| US9133154B2 (en) | 2013-03-12 | 2015-09-15 | Acucela Inc. | Substituted 3-phenylpropylamine derivatives for the treatment of ophthalmic diseases and disorders |
| CA2903910C (en) | 2013-03-12 | 2023-08-15 | Steven D. FIDANZE | Triazadibenzo[cd,f]azulene derivatives and pharmaceutical compositions thereof useful as bromodomain inhibitors |
| TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| TW201446768A (zh) * | 2013-03-15 | 2014-12-16 | Biogen Idec Inc | S1p及/或atx調節劑 |
| AP2016009020A0 (en) | 2013-07-18 | 2016-02-29 | Novartis Ag | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core |
| WO2015058031A1 (en) | 2013-10-17 | 2015-04-23 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
| EP3878848A1 (en) | 2013-11-22 | 2021-09-15 | Sabre Therapeutics LLC | Autotaxin inhibiting indole compounds |
| CA2923523A1 (en) | 2013-11-26 | 2015-06-04 | F. Hoffmann-La Roche Ag | New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl |
| AR098475A1 (es) | 2013-11-26 | 2016-06-01 | Bayer Cropscience Ag | Compuestos pesticidas y usos |
| CN106132935A (zh) | 2014-03-26 | 2016-11-16 | 巴斯夫欧洲公司 | 作为杀真菌剂的取代的[1,2,4]三唑和咪唑化合物 |
| JP6554481B2 (ja) | 2014-03-26 | 2019-07-31 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | オートタキシン（ａｔｘ）及びリゾホスファチジン酸（ｌｐａ）産生の阻害剤としての縮合［１，４］ジアゼピン化合物 |
| SG11201607839UA (en) | 2014-03-26 | 2016-10-28 | Hoffmann La Roche | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| MD20160116A2 (ro) | 2014-04-04 | 2017-04-30 | X-Rx Discovery, Inc | Inhibitori spirociclici substituiţi ai autotaxinei |
| EA031967B1 (ru) | 2014-10-14 | 2019-03-29 | Вайтаи Фармасьютиклз, Инк. | ДИГИДРОПИРРОЛОПИРИДИНОВЫЕ ИНГИБИТОРЫ ROR-γ |
| CR20170367A (es) | 2015-02-15 | 2017-09-12 | Hoffmann La Roche | Derivados de 1-(het)arilsulfonil-(pirrolidin o piperidin)-2-carboxamida y su uso como antagonistas de trpa1 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| CN104927727B (zh) | 2015-07-06 | 2017-01-11 | 香山红叶建设有限公司 | 一种玻璃幕墙用结构密封胶及其制备方法 |
| PL415078A1 (pl) | 2015-09-04 | 2017-03-13 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków |
| CA2992889A1 (en) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| JP6877413B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 二重ａｔｘ／ｃａ阻害剤としての新規な二環式化合物 |
| CA2983782A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| RU2018113709A (ru) | 2015-09-24 | 2019-10-30 | Айонис Фармасьютикалз, Инк. | Модуляторы экспрессии kras |
| WO2017050792A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| EP3353181B1 (en) | 2015-09-24 | 2021-08-11 | F. Hoffmann-La Roche AG | Bicyclic compounds as dual atx/ca inhibitors |
| BR112018009798A8 (pt) | 2015-11-25 | 2019-02-26 | Dana Farber Cancer Inst Inc | inibidores de bromodomínio bivalentes e usos dos mesmos |
| MX2018005222A (es) | 2015-12-01 | 2019-04-29 | Nihon Nohyaku Co Ltd | Compuesto de 3h-pirrolopiridina, n-óxido o sal del mismo, insecticida agrícola y hortícola que comprende el compuesto y método para usar los mismos. |
| WO2017139978A1 (zh) | 2016-02-19 | 2017-08-24 | 吴伟东 | 手机app更新方法及系统 |
| WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
| KR20190129924A (ko) | 2017-03-16 | 2019-11-20 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물 |
| ES2788856T3 (es) | 2017-03-20 | 2020-10-23 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
-
2015
- 2015-03-23 JP JP2016558222A patent/JP6554481B2/ja not_active Expired - Fee Related
- 2015-03-23 KR KR1020167029704A patent/KR20160128428A/ko not_active Ceased
- 2015-03-23 CR CR20160418A patent/CR20160418A/es unknown
- 2015-03-23 MX MX2016010675A patent/MX373236B/es active IP Right Grant
- 2015-03-23 WO PCT/EP2015/056041 patent/WO2015144609A1/en not_active Ceased
- 2015-03-23 SG SG11201607845RA patent/SG11201607845RA/en unknown
- 2015-03-23 CN CN201580008228.8A patent/CN106029667B/zh not_active Expired - Fee Related
- 2015-03-23 UA UAA201610688A patent/UA119347C2/uk unknown
- 2015-03-23 AU AU2015238541A patent/AU2015238541B2/en not_active Ceased
- 2015-03-23 EP EP15711207.9A patent/EP3122751B1/en active Active
- 2015-03-23 CA CA2935612A patent/CA2935612A1/en not_active Abandoned
- 2015-03-23 EA EA201691794A patent/EA032357B1/ru not_active IP Right Cessation
- 2015-03-23 PE PE2016001541A patent/PE20161223A1/es active IP Right Grant
- 2015-03-25 AR ARP150100864A patent/AR099823A1/es unknown
- 2015-03-25 TW TW104109652A patent/TWI678370B/zh not_active IP Right Cessation
-
2016
- 2016-06-28 IL IL246501A patent/IL246501B/en active IP Right Grant
- 2016-08-16 PH PH12016501633A patent/PH12016501633B1/en unknown
- 2016-09-14 CL CL2016002317A patent/CL2016002317A1/es unknown
- 2016-09-21 US US15/272,085 patent/US10669285B2/en active Active
-
2020
- 2020-03-02 US US16/806,302 patent/US20200199155A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2935612A1 (en) | 2015-10-01 |
| MX373236B (es) | 2020-05-08 |
| CL2016002317A1 (es) | 2017-03-17 |
| IL246501B (en) | 2020-01-30 |
| AU2015238541A1 (en) | 2016-07-14 |
| CR20160418A (es) | 2016-11-07 |
| EA201691794A1 (ru) | 2017-01-30 |
| US20200199155A1 (en) | 2020-06-25 |
| JP6554481B2 (ja) | 2019-07-31 |
| TW201625646A (zh) | 2016-07-16 |
| EP3122751B1 (en) | 2019-10-30 |
| AU2015238541B2 (en) | 2019-09-19 |
| US20170008913A1 (en) | 2017-01-12 |
| PH12016501633A1 (en) | 2017-02-06 |
| SG11201607845RA (en) | 2016-10-28 |
| CN106029667A (zh) | 2016-10-12 |
| TWI678370B (zh) | 2019-12-01 |
| CN106029667B (zh) | 2019-08-23 |
| JP2017510576A (ja) | 2017-04-13 |
| EP3122751A1 (en) | 2017-02-01 |
| MX2016010675A (es) | 2016-11-10 |
| IL246501A0 (en) | 2016-08-31 |
| PE20161223A1 (es) | 2016-11-12 |
| AR099823A1 (es) | 2016-08-24 |
| EA032357B1 (ru) | 2019-05-31 |
| PH12016501633B1 (en) | 2017-02-06 |
| UA119347C2 (uk) | 2019-06-10 |
| US10669285B2 (en) | 2020-06-02 |
| WO2015144609A1 (en) | 2015-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20160128428A (ko) | 오토탁신(atx) 및 리소포스파티드산(lpa) 생성 억제제로서의 축합형 [1,4]다이아제핀 화합물 | |
| AU2019257457B2 (en) | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | |
| US10800786B2 (en) | Bicyclic compounds as ATX inhibitors | |
| KR102179599B1 (ko) | 이환형 유도체 | |
| JP6258928B2 (ja) | 新規ジアザスピロシクロアルカンおよびアザスピロシクロアルカン | |
| KR20180054634A (ko) | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물 | |
| KR20180054830A (ko) | 오토탁신(atx) 억제제로서의 이환형 화합물 | |
| KR20150126036A (ko) | 오토탁신 억제제로서의 신규한 옥타하이드로-피롤로[3,4-c]-피롤 유도체 및 이의 유사체 | |
| KR20180053408A (ko) | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서의 신규한 이환형 화합물 | |
| KR20160087900A (ko) | 신규한 옥타하이드로-사이클로부타[1,2-c；3,4-c'']다이피롤-2-일 | |
| HK1226403A1 (en) | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors | |
| HK1226403B (zh) | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的稠合[1，4]二氮杂䓬化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20161025 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200319 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20211129 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20220211 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20211129 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |